https://endpts.com/for-decades-cancer-drug-developers-have-focused-on-inhibition-now-a-gv-backed-startup-is-eyeing-activation/
One of the backbones of cancer medicine is shutting down key cancer-driving pathways to kill tumor cells. But for years, researchers have noticed hyperactivation of certain signals in these pathways can lead to the same result. Researchers from Bill Sellers’ …
Create an account or login to join the discussion